We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out ...

Eli Lilly recently announced several significant events, including promising trial results for baricitinib in treating severe alopecia areata and long-term efficacy data for EBGLYSS in atopic ...

Eli Lilly shareholders can take confidence from the fact that EBIT margins are up from 32% to 39%, and revenue is growing. That's great to see, on both counts. In the chart below, you can see how ...

A major pharmaceutical company that has invested heavily in North Carolina is planning multiple new factories in the U.S. STORY HIGHLIGHTS Eli Lilly plans $27 billion U.S. expansion, will create ...